close

  
Filter options:

Freebase Commons Metaweb System Types /type

Object is not asserted on this topic.
  • Treatment Set TS330454 0.000133/0.00017/4.4e-06/4.4e-06/4.4e-06/0.00083/0.000133/0.00017/0.00017/0.00033/66.67/33.33/33.33/33.33/0.00033/0.0042/0.0017/0.00017/0.0083/0.000133/0.0021/0.0021 injectable solution

Freebase Commons Common /common

  • Treatment set ts330454 (Antigen Laboratories), manufactured drug form of Treatment set ts330454, 0.000133g/mL acer negundo pollen ; 0.00017g/mL alternaria alternata ; 4.4e-06g/mL ambrosia artemisiifolia pollen ; 4.4e-06g/mL ambrosia psilostachya pollen ; 4.4e-06g/mL ambrosia trifida pollen ; 0.00083g/mL aureobasidium pullulans var. pullutans ; 0.000133g/mL betula nigra pollen ; 0.00017g/mL carya illinoinensis pollen ; 0.00017g/mL carya tomentosa pollen ; 0.00033g/mL chenopodium album pollen ; 66.67[BAU]/mL cynodon dactylon pollen ; 33.33[AU]/mL dermatophagoides farinae ; 33.33[AU]/mL dermatophagoides pteronyssinus ; 33.33[BAU]/mL felis catus hair ; 0.00033g/mL fraxinus americana pollen ; 0.0042g/mL periplaneta americana ; 0.0017g/mL plantago lanceolata pollen ; 0.00017g/mL pleospora herbarum ; 0.0083g/mL salsola kali pollen ; 0.000133g/mL sorghum halepense pollen ; 0.0021g/mL sporisorium cruentum ; 0.0021g/mL ustilago cynodontis injectable solution, NDC 49288-0698

Freebase Commons Business /business

Freebase Commons Medicine /medicine

Section name Section URI Prominent warning Highlight text Subject manufactured drug Section LOINC code
  • true
  • Individual allergenic extract treatment vial is intended for use by physicians who are experienced in the administration of allergenic extracts for immunotherapy and the emergency care of anaphylaxis, or for use under the guidance of an allergy specialist. Individual allergenic extract treatment vials are not directly interchangeable with other allergenic extracts. The initial dose must be based on skin testing as described in the dosage and administration section of this insert. Patients being switched from other types of extract to individual treatment vials should be started as though they were coming under treatment for the first time. Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician's office if reaction symptoms occur. As with all allergenic extracts, severe systemic reactions may occur. In certain individuals, these reactions may be life-threatening. Patient should be observed for at least 20 minutes following treatment and emergency measures as well as personnel trained in their use should be immediately available in the event of a life-threatening reaction. This product should not be injected intravenously. Deep subcutaneous routes have proven to be safe. See the warnings, precautions, adverse reactions and overdosage sections below.
  • -
  • 34066-1
  • false
  • -
  • -
  • 34089-3
  • false
  • -
  • -
  • 34090-1
  • false
  • -
  • -
  • 34067-9
  • false
  • -
  • -
  • 34071-1
  • false
  • -
  • -
  • 34070-3
  • false
  • -
  • -
  • 42232-9
  • false
  • -
  • -
  • 34068-7
  • false
  • -
  • -
  • 34084-4
  • false
  • -
  • -
  • 34088-5

Comments

Hide